ENERTECH GLOBAL ANNOUNCES BRAND CONSOLIDATION TO STREAMLINE OPERATIONS, DRIVE INNOVATION
The decision to shift to two brands is part of Enertech's renewed commitment to increasing efficiency, accelerating product development, and enhancing the customer experience.
Brand Consolidation Key Benefits:
- Improved Supply Chain Efficiencies: Increased supply chain consistencies will result in more responsive lead times, improved cost efficiencies, and superior manufacturing.
- Fresh Focus on Engineering: Enertech's engineering teams can now devote more time and focus on developing new products and improving existing solutions.
- Brand Presence: Concentration of marketing resources will bolster brand awareness and drive lead generation for our customers.
"This change will improve every aspect of the Company's business from sales and marketing to engineering and manufacturing." said
"Through this transition it was important to retain the spirit of our legacy brands, especially GeoComfort, our first product brand and Hydron Module, which marked our entry point into the manufacturing of ground source heat pumps. We are retaining the GeoComfort name and have taken inspiration from Hydron Module in our updated product design," Dwyer added.
In regard to distribution and sales channels,
About Enertech Global
Founded in 1996 in
Connect with us online!
LinkedIn – www.linkedin.com/company/enertech-global-llc
Facebook - www.facebook.com/EnertechGlobal
X - www.x.com/EnertechGlobal
YouTube - www.youtube.com/enertechmfg
Instagram - www.instagram.com/enertechglobal
View original content to download multimedia:https://www.prnewswire.com/news-releases/enertech-global-announces-brand-consolidation-to-streamline-operations-drive-innovation-302362120.html
SOURCE Enertech
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Painting Expert Melvin Jones Explains Cabinet Painting vs. Replacement in HelloNation
- Raven Raises at $90M Valuation From CMCC Global and Coinbase Ventures for Prediction Markets
- Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share